Global expansion ChemPartner is expanding its geographic footprint with new facilities in Kent, UK and Boston, USA, signaling increased capacity and regional access for clients across North America and Europe—a sales opportunity to offer local partnerships, rapid start-up capabilities, and faster IND-enabling support.

Full service CRO As a global CRO offering discovery biology, pharmacology, DMPK, bioanalysis, synthesis, and biologics discovery, ChemPartner can be positioned as a one-stop partner for sponsors seeking seamless, integrated development across multiple modalities including small molecules, biologics, ADCs, and cell/gene therapies.

Therapeutic focus Capabilities in oncology, immunology, and infectious disease models align with high-growth areas in biopharma, presenting opportunities to upsell advanced pharmacology, MOA studies, and IND-enabling work to progressing programs and early-stage ventures.

Leadership appointments Recent hires and leadership appointments in biology, pharmacology, and DMPK signal strengthened depth of expertise, enabling credentials to leverage in client conversations for complex project scoping, risk mitigation, and high-quality data generation—a talking point for senior-level engagements.

Strategic partnerships Investments in updated branding, digital experience, and participation in major conferences (AACR 2026) indicate a focus on visibility and collaboration, creating openings for co-marketing, consortium opportunities, and multi-site program collaborations with biotech startups and mid-size pharma clients.